

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5893839

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BIOGEN IDEC MA INC. AND BIOGEN IDEC INTERNATIONAL GMBH	12/17/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MILLENNIUM PHARMACEUTICALS, INC.
<b>Street Address:</b>	40 LANDSDOWNE STREET
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02139
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	US1522792
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6504615211
<b>Email:</b>	cricks@wsgr.com
<b>Correspondent Name:</b>	CHRISTINE RICKS
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304-1050
<b>ATTORNEY DOCKET NUMBER:</b>	57841-702.601
<b>NAME OF SUBMITTER:</b>	CHRISTINE RICKS
<b>SIGNATURE:</b>	/Christine Ricks/
<b>DATE SIGNED:</b>	01/03/2020
<b>Total Attachments: 2</b>	
source=57841_702_601_signed_assignment#page1.tif	
source=57841_702_601_signed_assignment#page2.tif	

## PATENT ASSIGNMENT

Docket Nos. 3817.0070004/EKS/MFG

WHEREAS, Biogen Idec MA Inc. and Biogen Idec International GMBH (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the following patent applications (collectively hereinafter referred to as "Applications"), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

**PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR AND PROCESSES FOR THEIR PREPARATION**

for which U.S. Provisional Patent Application No. 61/970,595 was filed on March 26, 2014, and U.S. Provisional Patent Application No. 62/048,527 was filed on September 10, 2014, and Non-Provisional Patent Application No. 15/128,714 was filed on September 23, 2016, now U.S. Patent No. 10,426,782; and

for which International Patent Application No. PCT/US2015/022792 was filed on March 26, 2015 in the U.S. Receiving Office of the Patent Cooperation Treaty.

WHEREAS, MILLENNIUM PHARMACEUTICALS, INC., a corporation under the laws of the State of Delaware, having a place of business at 40 Landsdowne Street, Cambridge Massachusetts, 02139, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Inventions, and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patents").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Applications; (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Applications; (d) in and to said Patents and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patents.

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patents; (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patents granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby requests that any Patents issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.


IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

PATENT ASSIGNMENT

Docket Nos. 3817.0070004/EKS/MFG


ASSIGNOR

Date: Dec 17, 2019

By:   
Name: Bart Newland  
Title: Chief IP Counsel

RECEIVED AND AGREED TO BY ASSIGNEE:

Date: Dec 19, 2019

By:   
Name: Constance Yeung  
Title: Vice President, IP Region Head